Cohen N, Gorelik O, Almoznino-Sarafian D, Alon I, Tourovski Y, Weissgarten J, Chachashvily S, Shteinshnaider M, Modai D
Department of Internal Medicine F, Assaf Harofeh Medical Center Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Zerifin, Israel.
Clin Nephrol. 2004 Mar;61(3):177-84. doi: 10.5414/cnp61177.
Many congestive heart failure (CHF) patients suffer from various comorbidities, which may aggravate CHF or independently increase mortality risk. Renal failure (RF) is one of them. We defined bedside clinical, laboratory and electrocardiographic parameters characterizing CHF patients with and without concomitant RF, and analyzed their impact on mortality.
We studied symptomatic unselected consecutive furosemide-treated CHF patients hospitalized for various acute conditions. On admission, history taking, physical examination, chest x-ray, ECG and routine laboratory tests were performed. Subsequently, patients were divided into 2 subgroups, those with serum creatinine > or = 1.5 mg/dl (RF) and those with lower values. Following discharge, information concerning mortality and circumstance of death was obtained from hospital records and outpatient death certificates.
Included were 398 patients, 163 (40.9%) with RF and 235 free of RF. Prevailing in the RF subgroup were older age (mean age 75.5 vs 70.8, p < 0.001), male gender (p < 0.001), admission pulmonary edema (p = 0.007), cardiac arrhythmias (p = 0.05), cardiac conduction disturbances (p = 0.002), severe CHF (p = 0.005), lower ejection fraction (p = 0.03), anemia (p = 0.009), higher furosemide maintenance dosages (p < 0.001), insulin treatment (p = 0.03) and receiving less ACE inhibitors (p = 0.006). On median follow-up of 43 months, mortality was 54.9% in the RF vs 31.9% in the non-RF subgroup (p < 0.001), RF being the parameter most significantly associated with low survival (OR 1.97, p < 0.001). In the RF subgroup older age (p < 0.02), female gender (p < 0.003) and not using ACE inhibitors (p = 0.04) or drugs with antiarrhythmic effects (p < 0.005), emerged significantly associated with low survival, while diabetes mellitus (DM) and admission pulmonary edema tended to be so associated (p < 0.2). Using multivariate analysis in the RF subgroup, older age, female gender and DM proved most significantly associated with poorer survival (p = 0.004, OR 1.5, p = 0.03, OR 1.72, p = 0.04, OR 1.28, respectively). In the non-RF subgroup, only older age (p = 0.005) and DM (p = 0.05) were significantly associated with low survival. Sudden death occurred in 21 patients, 14 (8.6%) in the RF and 7 (3%) in the non-RF subgroup (p < 0.001).
RF is a marker of severity in CHF. Its full-blown deleterious prognostic effect is already manifested at serum creatinine 1.5 mg/dl. Older age, DM and female gender most significantly heralded a shorter survival. Such patients require special care.
许多充血性心力衰竭(CHF)患者患有多种合并症,这可能会加重CHF或独立增加死亡风险。肾衰竭(RF)就是其中之一。我们定义了有或无合并RF的CHF患者的床边临床、实验室和心电图参数,并分析了它们对死亡率的影响。
我们研究了因各种急性病症住院的有症状的、未经选择的连续接受速尿治疗的CHF患者。入院时,进行了病史采集、体格检查、胸部X光、心电图和常规实验室检查。随后,患者被分为2个亚组,血清肌酐≥1.5mg/dl的患者(RF)和血清肌酐值较低的患者。出院后,从医院记录和门诊死亡证明中获取有关死亡率和死亡情况的信息。
纳入398例患者,163例(40.9%)有RF,235例无RF。RF亚组中以年龄较大(平均年龄75.5岁对70.8岁,p<0.001)、男性(p<0.001)、入院时肺水肿(p=0.007)、心律失常(p=0.05)、心脏传导障碍(p=0.002)、严重CHF(p=0.005)、射血分数较低(p=0.03)、贫血(p=0.009)、速尿维持剂量较高(p<0.001)、胰岛素治疗(p=0.03)和接受ACE抑制剂较少(p=0.006)为主。在43个月的中位随访中,RF亚组的死亡率为54.9%,非RF亚组为31.9%(p<0.001),RF是与低生存率最显著相关的参数(OR 1.97,p<0.001)。在RF亚组中,年龄较大(p<0.02)、女性(p<0.003)以及未使用ACE抑制剂(p=0.04)或抗心律失常药物(p<0.005)与低生存率显著相关,而糖尿病(DM)和入院时肺水肿也倾向于如此相关(p<0.2)。在RF亚组中进行多变量分析时,年龄较大、女性和DM与较差的生存率最显著相关(分别为p=0.004,OR 1.5;p=0.03,OR 1.72;p=0.04,OR 1.28)。在非RF亚组中,只有年龄较大(p=0.005)和DM(p=0.05)与低生存率显著相关。21例患者发生猝死,RF亚组14例(8.6%),非RF亚组7例(3%)(p<0.001)。
RF是CHF严重程度的一个标志。其全面的有害预后影响在血清肌酐1.5mg/dl时就已显现。年龄较大、DM和女性最显著地预示着生存期较短。这类患者需要特别护理。